Perspective Therapeutics, Inc.
CATX · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $254,835 | $243,110 | $154,120 | $225,307 |
| - Cash | $26,762 | $28,849 | $44,406 | $61,580 |
| + Debt | $3,313 | $3,569 | $3,818 | $4,062 |
| Enterprise Value | $231,386 | $217,830 | $113,532 | $167,789 |
| Revenue | $209 | $290 | $342 | $0 |
| % Growth | -27.9% | -15.2% | – | – |
| Gross Profit | -$566 | -$443 | -$390 | $0 |
| % Margin | -270.8% | -152.8% | -114% | – |
| EBITDA | -$25,129 | -$21,147 | -$17,317 | -$41,618 |
| % Margin | -12,023.4% | -7,292.1% | -5,063.5% | – |
| Net Income | -$25,969 | -$21,485 | -$18,177 | -$40,169 |
| % Margin | -12,425.4% | -7,408.6% | -5,314.9% | – |
| EPS Diluted | -0.35 | -0.3 | -0.25 | -0.57 |
| % Growth | -16.7% | -20% | 56.1% | – |
| Operating Cash Flow | -$16,292 | -$13,831 | -$21,582 | -$26,606 |
| Capital Expenditures | -$1,992 | -$4,811 | -$4,656 | -$14,614 |
| Free Cash Flow | -$18,284 | -$18,642 | -$26,238 | -$41,220 |